Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab in children with enthesitis-related arthritis and juvenile psoriatic arthritis
2018-000681-10Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of ixekizumab and adalimumab in juvenile idiopathic arthritis, enthesitis-related (JIA-ERA), juvenile psoriatic arthritis (JPsA) and juvenile ankylosing spondylitis (JAS) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percentage of patients meeting the JIA ACR 30 response criteria at Week 16. Started Aug 2020; status: active.
02
Drugs
ixekizumabadalimumab
03
Conditions
juvenile idiopathic arthritis, enthesitis-related (JIA-ERA)juvenile psoriatic arthritis (JPsA)juvenile ankylosing spondylitis (JAS)
Beyond the preview
Go deeper on 2018-000681-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000681-10.